Factor VII and thromboembolism

Cardoso T., SARAÇOĞLU A.

TRENDS IN ANAESTHESIA AND CRITICAL CARE, cilt.22, ss.33-40, 2018 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.tacc.2018.04.010
  • Dergi Adı: TRENDS IN ANAESTHESIA AND CRITICAL CARE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.33-40
  • Anahtar Kelimeler: Recombinant activated factor VII, Thomboembolic events, Safety, NovoSeven (R), Haemorrhage, RECOMBINANT-FACTOR-VIIA, ACTIVATED FACTOR-VII, CELL-BASED MODEL, OFF-LABEL USE, ACUTE INTRACEREBRAL HEMORRHAGE, INHIBITOR BYPASS ACTIVITY, COAGULATION-FACTOR VIIA, FACTOR-IX INHIBITORS, DOSE FACTOR VIIA, CARDIAC-SURGERY
  • Marmara Üniversitesi Adresli: Hayır

Özet

Recombinant activated factor VIIa (rFVIIa) is a potent hemostatic agent originally developed for the treatment of haemophilia patients with inhibitors against factor FVIII or FIX. In approved indications, the safety profile of rFVIIa is favourable without major concerns. The prevalence of thromboembolic (TE) complications is less than 4/100.000 with fatal events being extremely rare. Also, the majority of reported events occurred in elderly patients with predisposing factors for TE complications.